The NIH says funding cuts would save it billions of dollars a year. D.C.-area industry and academic leaders say it would cripple R&D.
Potential delays in clinical trials may result in extended timelines for new drug approvals, and a sudden reduction in ...
These actions could postpone NIH-funded clinical trials and create cash flow issues for domestic biotech companies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback